Long-term Perspective with Nivolumab plus Ipilimumab

The combination of nivolumab + ipilimumab can now be used in 6 entities [1, 2]. The long-term data from the respective approval studies show unanimously that some of those affected can benefit from the treatment in the long term [3-8]. The combination therefore represents a therapy concept with a long-term perspective that combines the chance of long-term survival with sustained tumor control. The durability is explained here using the example of the RCC [1-3].